Fragment-based screening by ligand-observed 1D NMR and binding interface mapping by protein-observed 2D NMR are popular methods used in drug discovery. These methods allow researchers to detect compound binding over a wide range of affinities and offer a simultaneous assessment of solubility, purity, and chemical formula accuracy of the target compounds and the 15N-labeled protein when examined by 1D and 2D NMR, respectively. These methods can be applied for screening fragment binding to the active (GMPPNP-bound) and inactive (GDP-bound) states of oncogenic KRAS mutants.
Keywords: CSP; FBDD; FBS; HSQC titration; KRAS; NMR screening; STD; WaterLOGSY.
© 2024. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.